for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ADC Therapeutics SA

ADCT.N

Latest Trade

3.24USD

Change

0.02(+0.16%)

Volume

402,125

Today's Range

12.70

 - 

12.72

52 Week Range

5.18

 - 

12.74

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.24
Open
0.00
Volume
402,125
3M AVG Volume
--
Today's High
12.72
Today's Low
12.70
52 Week High
12.74
52 Week Low
5.18
Shares Out (MIL)
73.25
Market Cap (MIL)
--
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

ADC Therapeutics Announces Withdrawal Of Registration Statement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ADC Therapeutics SA

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

Biopole, route de la Corniche 3B

+41.21.6530200

https://adctherapeutics.com/

Executive Leadership

Peter B. Corr

Chairman of the Board of Directors

Chris Martin

Chief Executive Officer, Member of the Board of Directors

Michael Forer

Vice Chairman of the Board of Directors, Executive Vice President, Chief Financial Officer

Stephane Henchoz

Director of Finance

Patrick Van Berkel

Senior Vice President Research & Development

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Biotechnology firm ADC pulls listing amid latest IPO market jitters

Biotechnology company ADC Therapeutics SA <ADCT.N> postponed its planned $200 million U.S. initial public offering on Wednesday, citing adverse market conditions as it became the third company to pull a planned IPO in recent days.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up